Endogenous
tissue-type plasminogen activator and rise of myocardial infarction.
Quality improvement and
tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update.
Initially, several cross-sectional studies of patients with angina pectoris or previous myocardial infarction suggested that such patients had an impaired fibrinolytic system, and subsequently a few prospective cohort studies supported the notion that fibrinolytic factors such as plasminogen activator inhibitor (PAI-1) and
tissue-type plasminogen activator (tPA) mass concentrations were predictors of future events in this type of patients.
Tissue-type plasminogen activator (t-PA): Physiological and Clinical Aspects, Vol.
Structure and function of human
tissue-type plasminogen activator (t-PA).
NSO produced a concentration-dependent inhibition of
tissue-type plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor type 1 (PAI-1).
Clinical question Does primary angioplasty in myocardial infarction produce better long-term outcomes than
tissue-type plasminogen activator (t-PA)?
Amphoterin can interact with macrophage cell surface receptors for advanced glycation end products to enhance expression of
tissue-type plasminogen activator (6).
The continuously high PAI-1 concentrations make fibrins resistant to dissolution by
tissue-type plasminogen activator (tPA), which leads to multiorgan dysfunction and a bad prognosis in patients (2).
One unit of PAI-1 activity was defined as the amount that inhibited 1 IU of single
tissue-type plasminogen activator in 15 min at room temperature under the conditions used.
On the role of C1-inhibitor as inhibitor of
tissue-type plasminogen activator in human plasma.
